CoTx-101
/ Coave Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 24, 2026
Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic
(GlobeNewswire)
- "Dr. Nora Dimon, Coave’s VP of Clinical Development, will give an oral presentation evaluating the CoTx-101 program’s suprachoroidal delivery approach and dual-pathway therapeutic design, including non-human primate studies...In addition, Coave’s CEO, Rodolphe Clerval, will give an oral corporate presentation at the Euretina Innovation Spotlight (EIS) conference in Vienna, on 30 September 2026."
Preclinical • Wet Age-related Macular Degeneration
1 to 1
Of
1
Go to page
1